Frontlight ResearchEarly access
CompletedNo phase
The CLASP Study Edwards PASCAL TrAnScatheter Mitral Valve RePair System Study
Key facts
- Who runs it
- Edwards Lifesciences
- Where
- Aurora, Charlotte, Charlottesville, Detroit, Evanston, Los Angeles, Morristown, and Plano, United StatesSee the 8 sitesAlso in 6 other countries, 9 sites
- Trial code
- Status
- Completed
- People taking part
- 124 people enrolled
- Started
- 27 Jun 2017
- Ended
- 27 May 2025
- Type of study
- Interventional
- Treatments tested
- Mitral Valve Repair
- Record updated
- 5 February 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Signed and dated IRB/ethics committee approved study consent form prior to study related procedures
- Eighteen (18) years of age or older
- New York Heart Association (NYHA) Functional Class II-IVa heart failure despite optimal medical therapy
- Candidacy for surgical mitral valve repair or replacement determined by Heart Team evaluation
- Clinically significant mitral regurgitation (moderate-to-severe or severe mitral regurgitation) confirmed by transesophageal echocardiography (TEE) and transthoracic echocardiography (TTE)
- The primary regurgitant jet is non-commissural. If a secondary jet exists, it must be considered clinically insignificant
- Mitral valve area (MVA) ≥ 4.0 cm² as measured by planimetry. If MVA by planimetry is not measurable, pressure half-time measurement is acceptable
Who cannot take part
- Concurrent medical condition with a life expectancy of less than 12 months in the judgment of the Investigator
- Patient is currently participating or has participated in another investigational drug or device clinical study where the primary study endpoint was not reached at time of enrollment
- Physical evidence of right sided congestive heart failure and echocardiographic evidence of severe right ventricular dysfunction
- Patient in whom a TEE is contraindicated or screening TEE is unsuccessful
- Leaflet anatomy which may preclude PASCAL device implantation, proper device positioning on the leaflets, or sufficient reduction in mitral regurgitation
- Mitral valve area (MVA) < 4.0 cm² as measured by planimetry (If MVA by planimetry is not measurable, PHT measurement is acceptable)
- Echocardiographic evidence of intracardiac mass, thrombus, or vegetation
- Patient is under guardianship
Where in United States
Also in 6 other countries, 9 sites
- University of Colorado DenverAurora, United States
- Carolinas Medical CenterCharlotte, United States
- University of Virginia Health SystemCharlottesville, United States
- Henry Ford HospitalDetroit, United States
- NorthShore University HealthSystemEvanston, United States
- Cedars-Sinai Medical CenterLos Angeles, United States
- Morristown Medical CenterMorristown, United States
- The Heart Hospital Baylor PlanoPlano, United States
About the trial
What the trial wants to find out
The purpose of this study is to assess the safety, performance and clinical outcomes of the Edwards PASCAL Transcatheter Mitral Valve Repair (TMVr) System.
The group in the trial
- Edwards PASCAL Transcatheter Mitral Valve Repair SystemTreatment being tested
Treatment: Mitral Valve Repair
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- 1-Year Outcomes for Transcatheter Repair in Patients With Mitral Regurgitation From the CLASP Study.JACC. Cardiovascular interventions, 2020
- Transcatheter Valve Repair for Patients With Mitral Regurgitation: 30-Day Results of the CLASP Study.JACC. Cardiovascular interventions, 2019
- Record updated
- 5 February 2026